PROMIS NEUROSCIENCES, INC.

Highlights ProMIS Neurosciences, Inc.

Equities

PMN

CA74346M4065

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.845 ^USD	-7.75%		-2.38%	+60.43%

May. 15	ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	Apr. 30	CI
ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS	Apr. 09	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
ProMIS Neurosciences Announces Publication on Novel Target for ALS	Dec. 20	CI
Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease	Nov. 20	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)	22-04-18	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW